Femasys Inc. · NASDAQ:FEMY
Femasys — Investor Presentation (May 2026)
24 slides from Femasys's investor presentation, May 13, 2026
Slide 1: Corporate Presentation: Redefining Women's Reproductive Health at Global Scale
CONFIDENTAIL | NASDAQ: FEMY 1 CORPORATE PRESENTATION May 2026 ©️ 2026 Femasys Inc. Redefining Women’s Reproductive Health at Global Scale NASDAQ: FEMY
Slide 2: Forward Looking Statements
Forward Looking Statements NASDAQ: FEMY 2 This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and a
Slide 3: Femasys Overview
Femasys Overview NASDAQ: FEMY 3 STRONG INFRASTRUCTURE Experienced leadership team U.S. and global regulatory approvals In-house, scalable U.S. manufacturing Efficiency over years of optimization INNOVATIVE PRODUCTS Near-term revenue inflection with meaningful growth acceleration Limited competition
Slide 4: Key Leadership
Key Leadership NASDAQ: FEMY 4 Chief Financial Officer 30+ years of experience Cellectar Biosciences, Akari Therapeutics, Lev Pharmaceuticals, EpiCept DovElefant Chief Executive Officer & Founder 30+ years of experience Terumo Medical, Novoste, Salumedica Kathy Lee-Sepsick Sr. Vice President Global M
Slide 5: Commercializing Multi-Asset Women's Health Portfolio
NASDAQ: FEMY 5 Commercializing Multi-Asset Women’s Health Portfolio Unlocking large market opportunities through office-based innovation FERTILITY PRODUCT FAMILY PERMANENT BIRTH CONTROL First-line fertility treatment Non-Surgical permanent birth control Companion Diagnostic: FemCerv® for cervical ca
Slide 6: From Historical Headwinds to Future Opportunity
NASDAQ: FEMY 6 From Historical Headwinds to Future Opportunity Driven by a strong pipeline, expanding patient access and favorable provider economics MULTI-ASSET WOMEN’S HEALTH PORTFOLIO BIPARTISAN POLITICS STRATEGIC TARGET Diversified portfolio across indications and stages delivers scale and resil
Slide 7: Fertility in Crisis – Massive Unmet Need
Fertility in Crisis – Massive Unmet Need NASDAQ: FEMY 7 Centuries of limited innovation in first-line treatment have limited access for millions U.S. women with infertility1 (~50% male factor contribution2) ~10M Take first step and undergo infertility testing3 ~100K Receive IVF transfer cycle4 https
Slide 8: Fertility Portfolio with Strong Revenue Potential
Fertility Portfolio with Strong Revenue Potential NASDAQ: FEMY 8 Scalable growth driven by expanding access and adoption Estimate <10% Early REI Launch Established foundation, KOL advocacy and REI alignment Initial OB/GYN Launch Growth OB/GYN Expansion Existing patient base, validate seamless integr
Slide 9: Femasys Fertility FastTrack
Femasys Fertility FastTrack™ NASDAQ: FEMY 9 Connecting diagnosis to treatment in a streamlined pathway in OB/GYN office FemaSeed® OB/GYN qualifies patients in-office Leverages existing workflows (no lab required) First-line fertility treatment in OB/GYN office Intratubal Insemination DIAGNOSE PREPAR
Slide 10: FemaSeed Offers Favorable Competitive Advantages
FemaSeed Offers Favorable Competitive Advantages NASDAQ: FEMY 10 Artificial Insemination Assisted Reproductive FemaSeed IUI IVF ICSI No surgery (risks/cost) ✓ ✓ — — No egg retrieval or storage ✓ ✓ — — No required injections ✓ — — — Delivery to fallopian tube(s) (site of conception) ✓ — N/A N/A Cost-
Slide 11: FemaSeed Transforming the IUI Standard of Care
FemaSeed Transforming the IUI Standard of Care NASDAQ: FEMY 11 Reducing time lost in repeated, low-efficiency IUI cycles Artificial insemination has remained largely unchanged since first being performed in 1790. Why Historic IUI Falls Short… Sperm Counts worldwide have declined by >50%.1 Levine H.
Slide 12: Commercial Readiness to Unlock the Fertility Market
Commercial Readiness to Unlock the Fertility Market NASDAQ: FEMY 12 Proven clinical performance, strong revenue potential and high-intent patients drive adoption Prospective clinical trial demonstrated superior results against historic IUI1 CLINICAL VALIDATTION COMPELLING ECONOMICS ENGAGED PATIENTS
Slide 13: FemaSeed Delivering Clinically Superior Care
FemaSeed Delivering Clinically Superior Care NASDAQ: FEMY 13 Liu et al. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08. Duran
Slide 14: Compelling Economics for OB/GYN Practices
Compelling Economics for OB/GYN Practices NASDAQ: FEMY 14 ~70% States have Limited to NO fertility coverage1 Femasys fertility portfolio enables a new, high-value in-office revenue stream Resolve.org/learn/financial-resources/insurance-coverage/insurance-coverage-by-state Cash Pay Opportunity In cov
Slide 15: Fertility Portfolio Enables Accelerated FemBloc Adoption
Fertility Portfolio Enables Accelerated FemBloc Adoption NASDAQ: FEMY 15 Commercial Synergies Same OB/GYN call point as fertility portfoliowith pre-trained physicians at FemBloc launch Leverages delivery platform with FemaSeed for FemBloc treatment Shares device & procedure with FemVue for FemBloc c
Slide 16: Permanent Contraception – Critical Gap
U.S. women no longer intend to have children1,2 ~13M Remain on form oftemporary birth control2,3 Elect surgical sterilization every year2,4 ~1.2M Permanent Contraception – Critical Gap NASDAQ: FEMY 16 Centuries of limited innovation have created massive unmet need for millions of women Jones et. al,
Slide 17: FemBloc Potential for Exponential Revenue Expansion
FemBloc Potential for Exponential Revenue Expansion NASDAQ: FEMY 17 Leveraging existing fertility portfolio and physician base to drive outside growth Estimate ~30% Europe Launch Gather real-world evidence Initial OB/GYN Launch Growth OB/GYN Expansion Broaden access, drive adoption Scale reach, expa
Slide 18: FemBloc: Non-Surgical Permanent Birth Control
Natural with No Implant and No Hormones FemBloc: Non-Surgical Permanent Birth Control NASDAQ: FEMY 18 Patient-Centered Market Drivers High demand for natural & safe optionsthat empower women with choice Growing concern with hormone-based birth control options Patients seek non-implant solutions due
Slide 19: FemBloc Offers Favorable Competitive Advantages
FemBloc Offers Favorable Competitive Advantages NASDAQ: FEMY 19 Permanent Birth Control Temporary FemBloc(non-surgical) SurgicalSterilization Essure®(off-market) IUD Permanent ✓ ✓ ✓ — Office procedure ✓ — Some ✓ No special capital equipment ✓ — — ✓ No anesthesia ✓ N/A N/A ✓ No implant (coil/clip) ✓
Slide 20: FemBloc Extensive Clinical Data
FemBloc Extensive Clinical Data Redefining Birth Control NASDAQ: FEMY 20 Over 20 years of comprehensive research and successful regulatory review and approvals Liu et al. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi
Slide 21: FemBloc Advancing Toward U.S. Approval
Limited options and strong interest support efficient enrollment FemBloc Advancing Toward U.S. Approval NASDAQ: FEMY 21 De-risked through international regulatory approvals and clinical use Study design: U.S. FINALE pivotal trial for FDA approval1Prospective, multi-center, open-label, single-arm wit
Slide 22: Expansion of In-Office Revenue Opportunities
U.S. Cost Breakdown Compared to Surgical Sterilization Expansion of In-Office Revenue Opportunities NASDAQ: FEMY 22 Potential to reduce healthcare system costs while enhancing practice profitability Changing Economic Paradigm In-Office Proceduresmaximize physician time and efficiency Reimbursement E
Slide 23: Major Value Inflection Points
Major Value Inflection Points NASDAQ: FEMY 23 FEMASEED Additional partnership Cat III reimbursement Q1 2026 FEMBLOC MDSAP approval Initiate U.S. trial (FINALE) enrollment ACHIEVED ACHIEVED FEMASEED Launch FemSperm U.S. OB/GYN partnerships Q2 2026 FEMBLOC Additional U.S. trial sites Expand post-marke
Slide 24: Contact Details
Contact Details Investor RelationsIR@femasys.com Public Relations Media@femasys.com NASDAQ: FEMY